ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,261 to 3,280 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Viral Sequences51 of 1,080

63 of 1,108

-1.0 points

-2.8 to 0.9

2,188NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Intervention vs Control: Proportion of Neonates Exclusively Breastmilk Feeding at Discharge959 of 1,083

978 of 1,102

-0.2 points

-2.9 to 2.5

2,185NCT02811432

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

Intervention vs Control: Mortality Within 7 Days81 of 1,083

83 of 1,102

-0.1 points

-2.3 to 2.2

2,185NCT02811432

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

Trastuzumab Emtansine (All Participants) vs Trastuzumab Emtansine (Asian Participants): deaths from any cause1,072 of 2,002

77 of 181

11.0 points

3.4 to 18.3

2,183NCT01702571

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Trastuzumab Emtansine (All Participants) vs Trastuzumab Emtansine (Asian Participants): serious adverse events427 of 2,002

36 of 181

1.4 points

-5.2 to 6.9

2,183NCT01702571

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE)1,074 of 1,084

1,090 of 1,093

-0.6 points

-1.4 to 0.0

2,177NCT03498716

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events173 of 1,084

280 of 1,093

-9.7 points

-13.0 to -6.3

2,177NCT03498716

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Patients at High PAE Practices vs Patients at Low PAE Practices: deaths from any cause14 of 1,081

14 of 1,095

0.0 points

-1.0 to 1.0

2,176NCT02287883

Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs

Intervention Group vs Control Group: Number of Participants Reporting Physical Fights227 of 961

283 of 1,215

0.3 points

-3.2 to 3.9

2,176NCT02909673

School Based Program to Prevent Teen Dating Violence

Boostrix Group vs Adacel Group: Number of Seropositive Subjects With Anti-tetanus (Anti-T) Antibodies1,420 of 1,445

723 of 728

-1.0 points

-1.9 to 0.0

2,173NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants With Umbilical Cord Blood pH <7.03 of 1,085

4 of 1,088

-0.1 points

-0.7 to 0.5

2,173NCT03407625

Foley Bulb With Oral Misoprostol for Induction of Labor

Boostrix Group vs Adacel Group: Number of Seropositive Subjects With Anti-diphteria (Anti-D) Antibodies1,269 of 1,444

669 of 727

-4.1 points

-6.6 to -1.4

2,171NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Alirocumab 75 Q2W/Up150 Q2W vs Placebo: deaths from any cause17 of 1,087

24 of 1,084

-0.7 points

-1.9 to 0.5

2,171NCT02957682

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Alirocumab 75 Q2W/Up150 Q2W vs Placebo: serious adverse events189 of 1,087

216 of 1,084

-2.5 points

-5.8 to 0.7

2,171NCT02957682

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications125 of 606

289 of 1,564

2.1 points

-1.5 to 6.0

2,170NCT03442322

Optimizing Care for Patients With Dementia

Boostrix Group vs Adacel Group: Number of Subjects With Serious Adverse Events (SAEs)12 of 1,445

11 of 719

-0.7 points

-1.9 to 0.2

2,164NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Seqirus QIV vs Comparator QIV: Number of Participants With Cellulitis-like Reactions0 of 1,618

1 of 545

-0.2 points

-1.0 to 0.1

2,163NCT02914275

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Boostrix Group vs Adacel Group: Number of Subjects Reporting Emergency Room Visits13 of 1,444

6 of 718

0.1 points

-1.0 to 0.8

2,162NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Boostrix Group vs Adacel Group: Number of Subjects Reporting Hospitalizations13 of 1,444

10 of 718

-0.5 points

-1.7 to 0.4

2,162NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Boostrix Group vs Adacel Group: Number of Subjects Reporting the Onset of New Chronic Illnesses2 of 1,444

3 of 718

-0.3 points

-1.1 to 0.2

2,162NCT00346073

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=164"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=164

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03060629-3d2654de",
        "title": "Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Viral Sequences",
        "summary": "51 of 1080 against 63 of 1108; risk difference -1.0 points, 95% interval -2.8 to 0.9; NCT03060629, A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa",
        "record": "/library/comparisons/NCT03060629-3d2654de",
        "nct_id": "NCT03060629",
        "kind": "outcome",
        "participants": 2188,
        "risk_difference": {
          "value": -0.009636983553951067,
          "lower": -0.02849630005722078,
          "upper": 0.009164564578761355
        },
        "group_1": "51 of 1,080",
        "group_2": "63 of 1,108",
        "difference": "-1.0 points",
        "interval": "-2.8 to 0.9",
        "trial_title": "A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa"
      },
      {
        "id": "NCT02811432-69f0ab84",
        "title": "Intervention vs Control: Proportion of Neonates Exclusively Breastmilk Feeding at Discharge",
        "summary": "959 of 1083 against 978 of 1102; risk difference -0.2 points, 95% interval -2.9 to 2.5; NCT02811432, Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa",
        "record": "/library/comparisons/NCT02811432-69f0ab84",
        "nct_id": "NCT02811432",
        "kind": "outcome",
        "participants": 2185,
        "risk_difference": {
          "value": -0.0019740822109720613,
          "lower": -0.028695598463429135,
          "upper": 0.024693087986190833
        },
        "group_1": "959 of 1,083",
        "group_2": "978 of 1,102",
        "difference": "-0.2 points",
        "interval": "-2.9 to 2.5",
        "trial_title": "Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=165",
  "request_id": "O-Gnt8BnqO9JzPIF"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?